Loading clinical trials...
Loading clinical trials...
A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Conditions
Interventions
Lenalidomide
Locations
15
United States
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
Alta Bates Cancer Center
Berkeley, California, United States
Pacific Coast Hematology/Oncology Medical Group, Onc.
Fountain Valley, California, United States
Rush University Medical Center
Chicago, Illinois, United States
Harvard University
Boston, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
June 1, 2005
Primary Completion Date
April 1, 2008
Completion Date
April 1, 2008
Last Updated
May 13, 2025
NCT04496349
NCT00923442
NCT04188678
NCT00574730
NCT02030834
NCT00739141
Lead Sponsor
Celgene
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions